Note 11: Trade, Other Receivables and Other current assets
| (€‘000) | As of December 31, | |||||||
| 2017 | 2016 | |||||||
|
Trade receivable |
64 | 54 | ||||||
|
Advance deposits |
152 | 663 | ||||||
|
Other receivables |
17 | 643 | ||||||
|
|
|
|
|
|||||
|
Total Trade and Other receivables |
233 | 1,359 | ||||||
|
|
|
|
|
|||||
|
Prepaid expenses |
744 | 615 | ||||||
|
VAT receivable |
391 | 393 | ||||||
|
Other receivables |
1,120 | 413 | ||||||
|
|
|
|
|
|||||
|
Total Other current assets |
2,255 | 1,420 | ||||||
|
|
|
|
|
|||||
Impairment of receivables is assessed on an individual basis at the end of each accounting year.
At balance sheet dates presented, no receivable was overdue. There were no carrying amounts for trade and other receivables denominated in foreign currencies and no impairments were recorded.
At 31 December 2017, income tax receivables include an open balance for two fiscal years (2017 and 2016), while only one (2016) at 31 December 2016. As of 31 December 2016, other trade receivables mainly relate to credit notes to be received from suppliers and advance deposits made to the THINK trial clinical vendors.